A new high-strength version of Wegovy has been approved for use in the UK, offering eligible patients a more streamlined way to access the maximum weekly dose of the weight loss treatment.
The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised a 7.2mg single-injection pen, developed by Novo Nordisk, for adults living with obesity and a Body Mass Index (BMI) of 30 or above.
The latest approval means patients who require the highest dose can now receive it through a single weekly injection, rather than administering multiple injections to reach the same level. This marks a practical development in how the treatment can be delivered in clinical and community settings.
The regulator said the new pen provides an additional option for patients undergoing treatment for weight management, while maintaining its focus on safety and appropriate use.
However, the MHRA confirmed that the higher-dose pen is not intended for individuals with a BMI below 30, nor for those using Wegovy primarily to reduce the risk of cardiovascular conditions. As with all medicines, the agency stated that the safety and effectiveness of the treatment will continue to be closely monitored.
The approval builds on earlier developments this year, when the MHRA authorised the 7.2mg weekly dose itself. At that stage, patients were required to administer multiple injections using lower-dose pens to reach the maximum level.
The introduction of a single-dose pen is expected to simplify treatment regimens for some patients and may improve adherence, particularly for those already established on higher-dose therapy.
The move comes amid continued momentum in the GLP-1 market, with growing demand for weight management treatments and ongoing innovation in both injectable and oral therapies. Novo Nordisk has recently expanded its portfolio further, with a tablet version of its GLP-1 treatment now widely available in the United States.
For community pharmacy teams, the development highlights the continued evolution of weight management services and the increasing role of medicines in supporting patients with obesity.